FALVELLA, FELICIA STEFANIA
FALVELLA, FELICIA STEFANIA
Universita' degli Studi di MILANO
Atazanavir-induced severe episodes of kidney stones in an HIV-1-infected subject characterized by a CYP3A poor metabolizer phenotype
2014-11-15 S. Rusconi, R. Gagliardini, F.S. Falvella, D. Cattaneo, V. Di Cristo, A. De Luca, M. Fabbiani, E. Clementi, M. Galli, S. Di Giambenedetto
A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity
2020-01-01 E. Aloisio, M. Chibireva, L. Serafini, S. Pasqualetti, F.S. Falvella, A. Dolci, M. Panteghini
Deferasirox-induced serious adverse reaction in a pediatric patient : pharmacokinetic and pharmacogenetic analysis
2016-02-01 M. Marano, G. Bottaro, B. Goffredo, F. Stoppa, M. Pisani, A.M. Marinaro, F. Deodato, C. Dionisi Vici, E. Clementi, F.S. Falvella
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
2015-09-01 F.S. Falvella, S. Cheli, A. Martinetti, C. Mazzali, R. Iacovelli, C. Maggi, M. Gariboldi, M.A. Pierotti, M. Di Bartolomeo, E. Sottotetti, R. Mennitto, I. Bossi, F. de Braud, E. Clementi, F. Pietrantonio
HLA-B*57: 01 testing : Care in interpreting the quality of different genotyping methods
2017-02-01 F.S. Falvella, S. Cheli, E. Clementi
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
2019-10-01 F. Nichetti, F.S. Falvella, R. Miceli, S. Cheli, R. Gaetano, G. Fucà, G. Infante, A. Martinetti, C. Antoniotti, A. Falcone, M. Di Bartolomeo, C. Cremolini, F. de Braud, F. Pietrantonio
Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study
2021-05-01 F. Borgonovo, M. Passerini, M. Piscaglia, V. Morena, A. Giacomelli, L. Oreni, G. Dedivitiis, A. Lupo, S. Falvella, M.V. Cossu, A.F. Capetti
ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors
2015-01-01 A. Lombardi, S. Landonio, C. Magni, S. Cheli, C. Mazzali, M.U. Mondelli, G. Rizzardini, E. Clementi, F.S. Falvella
Levofloxacin-induced seizures in a patient without predisposing risk factors : the impact of pharmacogenetics
2013-08-01 C. Gervasoni, D. Cattaneo, F.S. Falvella, P. Vitiello, S. Cheli, L. Milazzo, E. Clementi, A. Riva
Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting
2017-01-01 L. Milazzo, C. Gervasoni, F.S. Falvella, D. Cattaneo, C. Mazzali, P. Ronzi, F. Binda, S. Cheli, S. Sollima, S. Antinori
The role of Toll-like receptor 4 polymorphisms in vaccine immune response
2016-02-01 P. Pellegrino, F.S. Falvella, S. Cheli, C. Perrotta, E. Clementi, S. Radice
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir
2015-04-01 L. Milazzo, A.M. Peri, C. Mazzali, C. Magni, E. Calvi, A. De Nicolò, E. Clementi, S. Cheli, A. D'Avolio, S. Antinori, F.S. Falvella
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase
2015-01-01 F.S. Falvella, M. Caporale, S. Cheli, A. Martinetti, R. Berenato, C. Maggi, M. Niger, F. Ricchini, I. Bossi, M. Di Bartolomeo, E. Sottotetti, F.F. Bernardi, F. de Braud, E. Clementi, F. Pietrantonio
An unexpectedly prolonged severe hyperbilirubinemia in a patient with pre-existing hepatitis A: A role of genetic predisposition?
2018-11-13 F.S. Falvella, E. Angeli, L. Cordier, E. Clementi, M. Panteghini